eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Otsuka and Bristol-Myers Squibb
Hunton House, Highbridge Estate, Oxford Road, Uxbridge, Middlesex, UB8 1DH, UK
Telephone: +44(0)1895 207100 (Otsuka)
Telephone: +44(0)1895 523000 (BMS)
Fax: +44 (0)1895 523010 (BMS)
Fax: +44(0)1895 523677 BMS
Fax: +44 (0)1895 207115 (Otsuka)
Medical Information Direct Line: +44(0)800 731 1736 BMS
Medical Information e-mail: medical.information@bms.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 07/10/2011
PIL Abilify 7.5 mg/ml solution for injection (intramuscular) (Otsuka & Bristol-Myers Squibb)

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to information about pregnancy or lactation
Updated on 02/02/2011 and displayed until 07/10/2011
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 22/12/2010 and displayed until 02/02/2011
Reasons for adding or updating:
  • Change to, or new, use for medicine
Updated on 02/02/2010 and displayed until 22/12/2010
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 21/12/2009 and displayed until 02/02/2010
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 09/06/2009 and displayed until 21/12/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to date of revision
Updated on 24/06/2008 and displayed until 09/06/2009
Reasons for adding or updating:
  • Changes to therapeutic indications
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to side-effects
Updated on 25/04/2008 and displayed until 24/06/2008
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  aripiprazole